The Phase III TEMPO-1 trial enrolled 529 adults aged between 40 and 80 years, diagnosed with Parkinson’s for less than three ...

AbbVie ABBV announced positive top-line results from the pivotal phase III TEMPO-1 study which evaluated its recently ...

Results from TEMPO-1, which showed that tavapadon significantly improved motor symptoms in patients with Parkinson’s disease, ...

AbbVie reports positive Phase 3 results for tavapadon, a once-daily treatment for early-stage Parkinson's disease. The drug ...

Tavapadon, a drug made by AbbVie to treat Parkinson’s disease, met phase 3 TEMPO-1 trial goals treated early Parkinson's ...

Leerink Partners analyst David Risinger has maintained their neutral stance on ABBV stock, giving a Hold rating on September 13. David ...

AbbVie plans to share results from another phase 3 trial of tavapadon later this year, the pharma said in the release. That ...

AbbVie reported Thursday that its experimental Parkinson’s drug that it got from Cerevel Therapeutics helped alleviate ...

The phase 3 Tempo-1 trial for tavapadon, a dopamine receptor partial agonist, demonstrated significant efficacy as a monotherapy in early Parkinson's disease. Patients receiving the drug at doses of 5 ...

AbbVie announced positive topline results from its Phase III TEMPO-1 trial for tavapadon as a monotherapy for early Parkinson ...

These results back up results from the TEMPO-3 trial, which tested tavapadon as an add-on therapy to levodopa and which also ...

AbbVie said tavapadon met the primary endpoint in the pivotal Phase 3 fixed-dose monotherapy trial, showing a statistically significant improvement in certain measures of the disease from baseline ...